17. Current status and future perspective of our basic research on scar and wound healing
Ayato Hayashi, Rica Tanaka, Morikuni Tobita, Yuri Nishimuta, Hisako Ishihara, Hidekazu Yoshizawa, Hiroshi Mizuno
Juntendo University School of Medicine, Department of Plastic and Reconstructive Surgery, Tokyo, Japan
Basic research on wound healing was started at our institution since Hiroshi Mizuno became the chief professor in 2009.
Our main research field is regenerative medicine focusing on adult stem cells including Adipose-derived stem cells (ASCs) and endothelial progenitor cell (EPC) as well as growth factors such as control-release basic fibroblast growth factor (bFGF).
With regard to ASCs, we have reported significant accelerating effects on wound healing in diabetic healing-impaired mice and periodontal tissue regeneration especially when combined with platelet-rich plasma. Regarding EPC, we found that EPC count and function are impaired in diabetic patients causing delayed wound healing. To overcome problems using EPS for autologous EPC therapy for diabetic patients, we have successfully established a serum free ex vivo expansion system (Hybrid Quality and Quantity Culture System; Hybrid QQc) for restoring the number and vasculogenic potential of EPCs for future clinical application of autologous EPC therapy for vascular and tissue regeneration. Research on control-released β-FGF is being performed in corroboration with Prof Tabata of Kyoto University, who has established the ideal controlled delivery system for this drug using gelatin hydrogel. We have reported positive effects of this system on ischemic limb, ischemia-reperfusion injury in island skin flap, and skin ulcer. Since β-FGF is widely used clinically as an aqueous solution, we are planning to use a control-release sheet or gel type of this drug for a clinical trial soon.